Drug Patents owned by Alnylam Pharms Inc

1. Drug name - GIVLAARI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8546143 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of a target gene
Jan, 2022

(8 months ago)

US9708610 ALNYLAM PHARMS INC Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Jan, 2024

(1 year, 2 months from now)

US10273477 ALNYLAM PHARMS INC Therapeutic compositions
Mar, 2024

(1 year, 5 months from now)

US9708615 ALNYLAM PHARMS INC Therapeutic compositions
Mar, 2024

(1 year, 5 months from now)

US9150605 ALNYLAM PHARMS INC Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Aug, 2025

(2 years from now)

US10131907 ALNYLAM PHARMS INC Glycoconjugates of RNA interference agents
Aug, 2028

(5 years from now)

US8828956 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(6 years from now)

US8106022 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(7 years from now)

US10125364 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Mar, 2033

(10 years from now)

US9133461 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
May, 2033

(10 years from now)

US10119143 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Oct, 2034

(12 years from now)

US11028392 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Oct, 2034

(12 years from now)

CN1630724A ALNYLAM PHARMS INC Method For Inhibiting Expression Of Target Gene
Jan, 2007

(15 years ago)

CN1608131A ALNYLAM PHARMS INC Medicine For Treating Pancreatic Cancer
Jan, 2009

(13 years ago)

CN1608133A ALNYLAM PHARMS INC Double-Stranded Ribonucleic Acid For Treating Positive (+) Chain Rna Virus Infection Of Suffers
Sep, 2009

(13 years ago)

CN1604783A ALNYLAM PHARMS INC The Medicine For Treating Fibrosis Disease By Rna Interference
Dec, 2009

(12 years ago)

CN1650010A ALNYLAM PHARMS INC Method For Inhibiting Expression Of Target Gene And Medicine For Treating Tumour Disease
Jan, 2010

(12 years ago)

CN102006890A ALNYLAM PHARMS INC Targeting Lipid
Oct, 2015

(6 years ago)

CN1835897A ALNYLAM PHARMS INC Manufacturing A Sintered Refractory Product Having Improved Foaming Properties For Blank
Aug, 2024

(1 year, 10 months from now)

CN1835897B ALNYLAM PHARMS INC Manufacturing With Improved Foaming Properties Of The Sintered Refractory Product For Blank
Aug, 2024

(1 year, 10 months from now)

CN104540948A ALNYLAM PHARMS INC Composition And Method For Inhibiting The Expression Of The Alas1
Apr, 2033

(10 years from now)

CN109112131B ALNYLAM PHARMS INC Composition And Method For Inhibiting Alas1 Gene Expression
Apr, 2033

(10 years from now)

CN109112131A ALNYLAM PHARMS INC Composition And Method For Inhibiting The Expression Of The Alas1
Apr, 2033

(10 years from now)

CN104540948B ALNYLAM PHARMS INC Composition And Method For Inhibiting The Expression Of The Alas1
Apr, 2033

(10 years from now)

CN105980559B ALNYLAM PHARMS INC Composition And Method For Inhibiting Alas1 Gene Expression
Oct, 2034

(12 years from now)

CN105980559A ALNYLAM PHARMS INC Composition And Method For Inhibition Of Alas1 Gene Expression
Oct, 2034

(12 years from now)

IN200300537P3 ALNYLAM PHARMS INC Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

IN213846B ALNYLAM PHARMS INC Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

IN200300572P3 ALNYLAM PHARMS INC Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

IN203882B ALNYLAM PHARMS INC Method For Inhibiting The Expression Of A Targe Gene
Jan, 2022

(8 months ago)

IN371332B ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of The Alas1 Gene
Apr, 2033

(10 years from now)

IN201407093P4 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of The Alas1 Gene
Apr, 2033

(10 years from now)

IN201647014609A ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of The Alas1 Gene
Oct, 2034

(12 years from now)

IN392668B ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of The Alas1 Gene
Oct, 2034

(12 years from now)

EP928290A4 ALNYLAM PHARMS INC Oligoribonucleotides And Ribonucleases For Cleaving Rna
Jun, 2017

(5 years ago)

EP928290B1 ALNYLAM PHARMS INC Oligoribonucleotides And Ribonucleases For Cleaving Rna
Jun, 2017

(5 years ago)

EP928290A1 ALNYLAM PHARMS INC Oligoribonucleotides And Ribonucleases For Cleaving Rna
Jun, 2017

(5 years ago)

EP928290B9 ALNYLAM PHARMS INC Oligoribonucleotides And Ribonucleases For Cleaving Rna
Jun, 2017

(5 years ago)

EP2363479A1 ALNYLAM PHARMS INC Oligoribonucucleotide For Inhibiting The Expression Of A Predefined Gene
Jan, 2020

(2 years ago)

EP2363479B1 ALNYLAM PHARMS INC Oligoribonucucleotide For Inhibiting The Expression Of A Predefined Gene
Jan, 2020

(2 years ago)

EP1214945A2 ALNYLAM PHARMS INC Method And Medicament For Inhibiting The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1214945A3 ALNYLAM PHARMS INC Method And Medicament For Inhibiting The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1214945B2 ALNYLAM PHARMS INC Method And Medicament For Inhibiting The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1550719B1 ALNYLAM PHARMS INC Doublestranded Rna (Dsrna) For Inhibition The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1214945B1 ALNYLAM PHARMS INC Method And Medicament For Inhibiting The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1550719A1 ALNYLAM PHARMS INC Doublestranded Rna (Dsrna) For Inhibition The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1144623A1 ALNYLAM PHARMS INC Method And Medicament For Inhibiting The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1144623B1 ALNYLAM PHARMS INC Method And Medicament For Inhibiting The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1798285B1 ALNYLAM PHARMS INC Methods And Medicament For Inhibition The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1144623B9 ALNYLAM PHARMS INC Method And Medicament For Inhibiting The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1798285A1 ALNYLAM PHARMS INC Methods And Medicament For Inhibition The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1349927B1 ALNYLAM PHARMS INC Method For Inhibiting The Expression Of A Target Gene And Medicament For Treating A Tumor Disease
May, 2021

(1 year, 4 months ago)

EP1349927A2 ALNYLAM PHARMS INC Method For Inhibiting The Expression Of A Target Gene And Medicament For Treating A Tumor Disease
May, 2021

(1 year, 4 months ago)

EP1352061B9 ALNYLAM PHARMS INC Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

EP1352061B1 ALNYLAM PHARMS INC Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

EP1352061A2 ALNYLAM PHARMS INC Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

EP2213736A3 ALNYLAM PHARMS INC Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness
Jan, 2022

(8 months ago)

EP2213736B1 ALNYLAM PHARMS INC Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness
Jan, 2022

(8 months ago)

EP2213736A2 ALNYLAM PHARMS INC Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness
Jan, 2022

(8 months ago)

EP1560840A4 ALNYLAM PHARMS INC Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation
Nov, 2023

(1 year, 1 month from now)

EP2957568B1 ALNYLAM PHARMS INC Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation
Nov, 2023

(1 year, 1 month from now)

EP1560840B1 ALNYLAM PHARMS INC Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation
Nov, 2023

(1 year, 1 month from now)

EP2957568A1 ALNYLAM PHARMS INC Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation
Nov, 2023

(1 year, 1 month from now)

EP1562971A4 ALNYLAM PHARMS INC Polycyclic Sugar Surrogate-Containing Oligomeric Compounds And Compositions For Use In Gene Modulation
Nov, 2023

(1 year, 1 month from now)

EP1560840A2 ALNYLAM PHARMS INC Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation
Nov, 2023

(1 year, 1 month from now)

EP1562971B1 ALNYLAM PHARMS INC Polycyclic Sugar Surrogate-Containing Oligomeric Compounds And Compositions For Use In Gene Modulation
Nov, 2023

(1 year, 1 month from now)

EP1562971A2 ALNYLAM PHARMS INC Polycyclic Sugar Surrogate-Containing Oligomeric Compounds And Compositions For Use In Gene Modulation
Nov, 2023

(1 year, 1 month from now)

EP2216407B1 ALNYLAM PHARMS INC Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP1605978A2 ALNYLAM PHARMS INC Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP1605978B1 ALNYLAM PHARMS INC Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP1605978A4 ALNYLAM PHARMS INC Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP2216407A3 ALNYLAM PHARMS INC Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP2216407A2 ALNYLAM PHARMS INC Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP1615611A4 ALNYLAM PHARMS INC Irna Conjugates
Apr, 2024

(1 year, 6 months from now)

EP1615611B1 ALNYLAM PHARMS INC Irna Conjugates
Apr, 2024

(1 year, 6 months from now)

EP1615611A2 ALNYLAM PHARMS INC Irna Conjugates
Apr, 2024

(1 year, 6 months from now)

EP1620544A4 ALNYLAM PHARMS INC Modified Irna Agents
Apr, 2024

(1 year, 6 months from now)

EP1620544A2 ALNYLAM PHARMS INC Modified Irna Agents
Apr, 2024

(1 year, 6 months from now)

EP1620544B1 ALNYLAM PHARMS INC Modified Irna Agents
Apr, 2024

(1 year, 6 months from now)

EP1765074A2 ALNYLAM PHARMS INC Positionally Modified Sirna Constructs
Jun, 2024

(1 year, 8 months from now)

EP1765074A4 ALNYLAM PHARMS INC Positionally Modified Sirna Constructs
Jun, 2024

(1 year, 8 months from now)

EP1765074B1 ALNYLAM PHARMS INC Positionally Modified Sirna Constructs
Jun, 2024

(1 year, 8 months from now)

EP1667944B1 ALNYLAM PHARMS INC Hollow Piece For Producing A Sintered Refractory Product Exhibiting Improved Bubbling Behaviour
Aug, 2024

(1 year, 10 months from now)

EP1667944A1 ALNYLAM PHARMS INC Hollow Piece For Producing A Sintered Refractory Product Exhibiting Improved Bubbling Behaviour
Aug, 2024

(1 year, 10 months from now)

EP1677822A2 ALNYLAM PHARMS INC 4'-Thionucleosides And Oligomeric Compounds
Sep, 2024

(1 year, 11 months from now)

EP1677822A4 ALNYLAM PHARMS INC 4'-Thionucleosides And Oligomeric Compounds
Sep, 2024

(1 year, 11 months from now)

EP1677822B1 ALNYLAM PHARMS INC 4'-Thionucleosides And Oligomeric Compounds
Sep, 2024

(1 year, 11 months from now)

EP1799270A2 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Anti-Apoptotic Genes
Sep, 2025

(2 years from now)

EP1799270B1 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Anti-Apoptotic Genes
Sep, 2025

(2 years from now)

EP1799270A4 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Anti-Apoptotic Genes
Sep, 2025

(2 years from now)

EP2231195B1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(6 years from now)

EP2231194A2 ALNYLAM PHARMS INC Folate-Irna Conjugates
Dec, 2028

(6 years from now)

EP2231194B1 ALNYLAM PHARMS INC Folate-Irna Conjugates
Dec, 2028

(6 years from now)

EP3156077A1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(6 years from now)

EP3156077B1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(6 years from now)

EP2231195A2 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(6 years from now)

EP2836595A2 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of The Alas1 Gene
Apr, 2033

(10 years from now)

EP2836595B1 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of The Alas1 Gene
Apr, 2033

(10 years from now)

EP3052628B1 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of The Alas1 Gene
Oct, 2034

(12 years from now)

EP3052628A1 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of The Alas1 Gene
Oct, 2034

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9631193 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene Mar, 2033

(10 years from now)

Drugs and Companies using GIVOSIRAN SODIUM ingredient

Treatment: Treatment of acute hepatic porphyria

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 189MG BASE/ML (EQ 189MG BASE/ML) SOLUTION;SUBCUTANEOUS Prescription

2. Drug name - ONPATTRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8334373 ALNYLAM PHARMS INC Nuclease resistant double-stranded ribonucleic acid
May, 2025

(2 years from now)

US10240152 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin
Oct, 2029

(7 years from now)

US8168775 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin
Oct, 2029

(7 years from now)

US11079379 ALNYLAM PHARMS INC Methods of treating transthyretin (TTR) mediated amyloidosis
Aug, 2035

(12 years from now)

CN102186978B ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

CN103937793B ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

CN106834291A ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

CN106834291B ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

CN102186978A ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

CN103937793A ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

CN107106874B ALNYLAM PHARMS INC Method For Treating Transthyretin (Ttr) Mediated Amyloidosis
Aug, 2035

(12 years from now)

CN107106874A ALNYLAM PHARMS INC Method Of Treating Transthyretin (Ttr) Mediated Amyloidosis
Aug, 2035

(12 years from now)

IN307782B ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

IN201103301P4 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

EP2399924B1 ALNYLAM PHARMS INC Nuclease Resistant Double-Stranded Ribonucleic Acid
May, 2025

(2 years from now)

EP2399924A3 ALNYLAM PHARMS INC Nuclease Resistant Double-Stranded Ribonucleic Acid
May, 2025

(2 years from now)

EP2399924A2 ALNYLAM PHARMS INC Nuclease Resistant Double-Stranded Ribonucleic Acid
May, 2025

(2 years from now)

EP2344639A2 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

EP3354733A1 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

EP2344639B1 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

EP3354733B1 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

EP2937418A1 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

EP2937418B1 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of Transthyretin
Oct, 2029

(7 years from now)

EP3185957A2 ALNYLAM PHARMS INC Patisiran For Use In Treating Transthyretin Mediated Amyloidosis
Aug, 2035

(12 years from now)

EP3185957A4 ALNYLAM PHARMS INC Methods Of Treating Transthyretin (Ttr) Mediated Amyloidosis
Aug, 2035

(12 years from now)

EP3185957B1 ALNYLAM PHARMS INC Patisiran For Use In Treating Transthyretin Mediated Amyloidosis
Aug, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9943538 ALNYLAM PHARMS INC 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations Nov, 2023

(1 year, 1 month from now)

US9943539 ALNYLAM PHARMS INC 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations Nov, 2023

(1 year, 1 month from now)

US8642076 ALNYLAM PHARMS INC Lipid containing formulations Oct, 2027

(5 years from now)

US8058069 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery Apr, 2029

(6 years from now)

US8822668 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery Apr, 2029

(6 years from now)

US9364435 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery Apr, 2029

(6 years from now)

US11141378 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery Apr, 2029

(6 years from now)

US8492359 ALNYLAM PHARMS INC Lipid formulations for nucleic acid delivery Apr, 2029

(6 years from now)

US8741866 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin Oct, 2029

(7 years from now)

US9234196 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of transthyretin Oct, 2029

(7 years from now)

US8802644 ALNYLAM PHARMS INC Lipid formulation Oct, 2030

(8 years from now)

US8158601 ALNYLAM PHARMS INC Lipid formulation Nov, 2030

(8 years from now)

Drugs and Companies using PATISIRAN SODIUM ingredient

Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE/5ML (EQ 2MG BASE/ML) SOLUTION;INTRAVENOUS Prescription

3. Drug name - OXLUMO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10131907 ALNYLAM PHARMS INC Glycoconjugates of RNA interference agents
Aug, 2028

(5 years from now)

US8828956 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(6 years from now)

US8106022 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(7 years from now)

US10465195 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(12 years from now)

US11060093 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(12 years from now)

US10487330 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(12 years from now)

US9828606 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(12 years from now)

US10612024 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(12 years from now)

US10612027 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(12 years from now)

US10478500 ALNYLAM PHARMS INC Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression
Oct, 2035

(13 years from now)

CN102006890A ALNYLAM PHARMS INC Targeting Lipid
Oct, 2015

(6 years ago)

CN108064154A ALNYLAM PHARMS INC Composition And Method For Inhibiting Hao1 (Hydroxy Acid Oxidase 1 (Glycolate Oxidase)) Gene Expression
Oct, 2035

(13 years from now)

CN108064154B ALNYLAM PHARMS INC Composition And Method For Inhibiting Expression Of Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene
Oct, 2035

(13 years from now)

IN372206B ALNYLAM PHARMS INC Double-Stranded Rnai Agents And Compositions For Inhibiting Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
Oct, 2035

(13 years from now)

IN201747014263A ALNYLAM PHARMS INC Compositions And Methods For Inhibition Of Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
Oct, 2035

(13 years from now)

EP2231195B1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(6 years from now)

EP3156077A1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(6 years from now)

EP2231194A2 ALNYLAM PHARMS INC Folate-Irna Conjugates
Dec, 2028

(6 years from now)

EP3156077B1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(6 years from now)

EP2231194B1 ALNYLAM PHARMS INC Folate-Irna Conjugates
Dec, 2028

(6 years from now)

EP2231195A2 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(6 years from now)

EP3087184A1 ALNYLAM PHARMS INC Methods And Compositions For The Specific Inhibition Of Glycolate Oxidase (Hao1) By Double-Stranded Rna
Dec, 2034

(12 years from now)

EP3087184B1 ALNYLAM PHARMS INC Methods And Compositions For The Specific Inhibition Of Glycolate Oxidase (Hao1) By Double-Stranded Rna
Dec, 2034

(12 years from now)

EP3087184A4 ALNYLAM PHARMS INC Methods And Compositions For The Specific Inhibition Of Glycolate Oxidase (Hao1) By Double-Stranded Rna
Dec, 2034

(12 years from now)

EP3581654A1 ALNYLAM PHARMS INC Methods And Compositions For The Specific Inhibition Of Glycolate Oxidase (Hao1) By Double-Stranded Rna
Dec, 2034

(12 years from now)

EP3581654B1 ALNYLAM PHARMS INC Methods And Compositions For The Specific Inhibition Of Glycolate Oxidase (Hao1) By Double-Stranded Rna
Dec, 2034

(12 years from now)

EP3204015A4 ALNYLAM PHARMS INC Compositions And Methods For Inhibition Of Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
Oct, 2035

(13 years from now)

EP3204015A1 ALNYLAM PHARMS INC Compositions And Methods For Inhibition Of Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
Oct, 2035

(13 years from now)

EP3204015B1 ALNYLAM PHARMS INC Compositions And Methods For Inhibition Of Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
Oct, 2035

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10435692 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA Dec, 2034

(12 years from now)

Drugs and Companies using LUMASIRAN SODIUM ingredient

Treatment: Treatment of primary hyperoxaluria type 1 (ph1)

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 94.5MG/0.5ML BASE (EQ 94.5MG/0.5ML BASE) SOLUTION;SUBCUTANEOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.